Cardiovascular physiology

Daxor Corporation to Exhibit and Showcase Compelling New Data at the Heart Failure Society of America Virtual Annual Scientific Meeting 2020 on the Value of BVA-100®

Monday, September 28, 2020 - 1:30pm

The Company will host a booth and will be available online throughout the entire conference to discuss how Daxors BVA-100 blood test improves heart failure outcomes and answer questions.

Key Points: 
  • The Company will host a booth and will be available online throughout the entire conference to discuss how Daxors BVA-100 blood test improves heart failure outcomes and answer questions.
  • Register for the event here: https://hfsa.org/annualscientificmeeting/registration
    Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement.
  • Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients.
  • Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Dr. Jessica Isom Brings Real-World Clinical Experience and Expertise in Social Justice, Health Equity, and Mental Health to the Virgin Pulse Science Advisory Board

Wednesday, September 23, 2020 - 5:10pm

We are thrilled to welcome Dr. Isom to the Virgin Pulse Science Advisory Board, said Rajiv Kumar, M.D., Virgin Pulses Chief Medical Officer and President of the Virgin Pulse Institute.

Key Points: 
  • We are thrilled to welcome Dr. Isom to the Virgin Pulse Science Advisory Board, said Rajiv Kumar, M.D., Virgin Pulses Chief Medical Officer and President of the Virgin Pulse Institute.
  • Though well documented, the connection between diversity, equity, inclusion, and physical, mental and social health is often underestimated by organizations and business leaders.
  • Dr. Isom is practicing physician with extensive experience in racial health disparities and ethnic mental health issues.
  • For more information about the Virgin Pulse Science Advisory Board and the Virgin Pulse Institute.

SANUWAVE Health Hosts Symposium on dermaPACE at Wounds Canada Virtual Conference

Tuesday, September 22, 2020 - 1:45pm

The biologic responses activated by the dermaPACE treatment continue to demonstrate improved revascularization and capillary perfusion needed to promote healing in these recalcitrant wounds.

Key Points: 
  • The biologic responses activated by the dermaPACE treatment continue to demonstrate improved revascularization and capillary perfusion needed to promote healing in these recalcitrant wounds.
  • The dermaPACE System has been particularly effective in speeding the healing process through improved microvascular perfusion in patients with diabetic, distal ischemia.
  • To participate in the conference and symposium free of charge, please send a request and your contact information toWoundsCanada2020@Sanuwave.com.
  • The dermaPACE Systemand wound indications are currently licensed or approved in dozens of countries and regions around the world.

CardieX Granted Patent in Europe for Key Brachial Cuff Blood Pressure Technology

Friday, September 18, 2020 - 6:02pm

IRVINE, Calif., Sept. 18, 2020 /PRNewswire/ --CardieX Limited (ASX: CDX ) (CardieX, the Company) announced today that CardieX subsidiary ATCOR was granted a new patent by the European Patent Office (EPO) for the Company's proprietary SphygmoCor technology used in cuff-based blood pressure devices.

Key Points: 
  • IRVINE, Calif., Sept. 18, 2020 /PRNewswire/ --CardieX Limited (ASX: CDX ) (CardieX, the Company) announced today that CardieX subsidiary ATCOR was granted a new patent by the European Patent Office (EPO) for the Company's proprietary SphygmoCor technology used in cuff-based blood pressure devices.
  • EPO Patent Number EP2566387 further protects the company's intellectual property in relation to the measurement of a central blood pressure (BP) waveform with cardiovascular features using a brachial cuff.
  • Patent EP2566387specifically coversnon-invasively estimating the heart's pressure and pressure waveform related to cardiac function and arterial properties using a conventional BP cuff inflated to low pressure.
  • ATCOR currently sells the XCEL central blood pressure device and has a partnership with SunTech Medical for the Oscar 2 ABPM device, which both incorporate ATCOR's SphygmoCor and brachial cuff technology.

DGAP-News: 4TEEN4's first-in-class therapeutic antibody Procizumab restores heart function in life-threatening cardiac depression induced by sepsis

Wednesday, September 16, 2020 - 9:01am

The study data (1) from the team lead by Prof. Alexandre Mebazaa have shown that high DPP3 blood values are associated with decreased heart function in a preclinical sepsis model.

Key Points: 
  • The study data (1) from the team lead by Prof. Alexandre Mebazaa have shown that high DPP3 blood values are associated with decreased heart function in a preclinical sepsis model.
  • In this randomized, controlled study, the administration of Procizumab immediately and significantly improved heart function by increasing cardiac output, stroke volume, and left ventricular shortening fraction.
  • By inhibiting DPP3 with our antibody Procizumab, we are able to restore cardiac function in preclinical sepsis models.
  • This inactivation leads to cardiac depression and consequently hemodynamic instability and consequently cardiac depression.

Roxgold Reports 26.9 GPT Over 4.8 Metres at Boussoura as Drill Program Continues to Expand Additional Fofora Vein Sets

Monday, September 14, 2020 - 11:00am

Going forward, the focus will be on drilling the additional 5 vein sets identified at Fofora, testing targets near Galgouli and conducting an aircore drill program to prioritise the regional targets that have demonstrated high prospectivity from recent geochemical results.

Key Points: 
  • Going forward, the focus will be on drilling the additional 5 vein sets identified at Fofora, testing targets near Galgouli and conducting an aircore drill program to prioritise the regional targets that have demonstrated high prospectivity from recent geochemical results.
  • Paul Weedon, Vice President Exploration commented We have now identified over 9 mineralized vein sets over 4 vein corridors across only a third of the 9 km2 active area at Fofora.
  • Drilling resumed at Fofora in early May, testing 5 new vein corridors within 2 kilometres to the west of the main Fofora Vein.
  • These targets form part of the broader Fofora artisanal field and are very similar in appearance to the high grade Fofora main vein (Figure 3).

Analysis on Impact of COVID-19- Ambulatory Blood Pressure Monitoring Systems Market 2020-2024 | Evolving Opportunities with A&D Co. Ltd. and General Electric Co. | Technavio

Wednesday, September 9, 2020 - 3:15pm

The global ambulatory blood pressure monitoring systems market is expected to grow by USD 36.58 million as per Technavio.

Key Points: 
  • The global ambulatory blood pressure monitoring systems market is expected to grow by USD 36.58 million as per Technavio.
  • View the full release here: https://www.businesswire.com/news/home/20200909005513/en/
    Technavio has announced its latest market research report titled Global Ambulatory Blood Pressure Monitoring Systems Market 2020-2024 (Graphic: Business Wire)
    Read the 120-page report with TOC on "Ambulatory Blood Pressure Monitoring Systems Market Analysis Report by Product (Arm-based and Wrist-based), Geography (North America, Europe, Asia, and ROW), and the Segment Forecasts, 2020-2024".
  • In addition, technological advances are anticipated to boost the growth of the ambulatory blood pressure monitoring systems market.
  • In 2017, about 75 million adults in the US had blood pressure, of which only 54% had their blood pressure under control.

Latest Data from HouseCanary Reveals Seasonal Shift in Housing Demand May Be on the Horizon

Thursday, September 3, 2020 - 1:00pm

The Market Pulse is an ongoing review of proprietary data and insights from HouseCanarys nationwide platform.

Key Points: 
  • The Market Pulse is an ongoing review of proprietary data and insights from HouseCanarys nationwide platform.
  • View the full release here: https://www.businesswire.com/news/home/20200903005266/en/
    Note: Effective September 3, 2020, the Market Pulse report will be released on a bi-weekly basis.
  • The slight pullback of home sales activity over the past few weeks may reflect early signs of a seasonal shift in demand as the initial surge of pandemic buying weakens.
  • Be sure to review the Market Pulse in full for extensive state-level data.

Center for Vein Restoration (CVR) Venous and Lymphatic Medicine Fellowship Largest in Country

Wednesday, September 2, 2020 - 11:00am

GREENBELT, Md., Sept. 2, 2020 /PRNewswire-PRWeb/ --As of July 2020, Center for Vein Restoration's Venous and Lymphatic Medicine program became the largest American Board of Venous and Lymphatic Medicine (ABVLM) approved training program in the United States.

Key Points: 
  • GREENBELT, Md., Sept. 2, 2020 /PRNewswire-PRWeb/ --As of July 2020, Center for Vein Restoration's Venous and Lymphatic Medicine program became the largest American Board of Venous and Lymphatic Medicine (ABVLM) approved training program in the United States.
  • As a nationally recognized clinical researcher with over 25 years of academic experience in Vascular Surgery, he is uniquely qualified to serve as the Program Director of CVR's Venous and Lymphatic Medicine Program.
  • "What sets our fellowship program apart is its association with the clinical leaders in vein care.
  • To learn more and apply to CVR's Venous & Lymphatic Medicine Fellowship Program:

Pulse Biosciences to Participate in the H.C. Wainwright Global Investment Conference

Tuesday, September 1, 2020 - 9:05pm

Pulse Biosciences, Inc. (Nasdaq: PLSE) a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced plans to virtually participate in the upcoming H.C. Wainwright Global Investment Conference.

Key Points: 
  • Pulse Biosciences, Inc. (Nasdaq: PLSE) a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced plans to virtually participate in the upcoming H.C. Wainwright Global Investment Conference.
  • Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve and extend the lives of patients.
  • Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
  • Caution: Pulse Biosciences CellFX System and Nano-Pulse Stimulation technology are for investigational use only.